BRIEF—Atriva agrees reverse takeover with Biocure

Germany’s Atriva Therapeutics and Canadian firm Biocure Technologies have entered into an exclusive letter agreement for a reverse takeover transaction.

Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics.

Under the terms of the agreement, shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder.

The transaction is subject to various terms and conditions, including satisfactory due diligence, successful implementation of a private placement and shareholder approvals.

“We are delighted to have entered into this exclusive letter agreement with Biocure. Our discussions with the Biocure management and board of directors have been exceptionally productive and constructive. We are eager to embark on this journey and combine the strengths of both companies. Together, we aim to address the urgent medical need for safe and effective therapies for patients suffering from severe RNA virus infections,” said Christian Pangratz, chief executive of Atriva.